Larimar Therapeutics, Inc.
LRMR
$3.44
-$0.06-1.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -29.61M | -62.50M | -47.71M | -26.18M | -29.28M |
| Total Depreciation and Amortization | 64.00K | 87.00K | 88.00K | 87.00K | 88.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.81M | 1.32M | 1.39M | 1.29M | 1.02M |
| Change in Net Operating Assets | -16.88M | 22.56M | 17.48M | 5.42M | 1.63M |
| Cash from Operations | -44.61M | -38.53M | -28.75M | -19.38M | -26.54M |
| Capital Expenditure | -- | 0.00 | -23.00K | -19.00K | -49.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 29.00M | 34.00M | 33.04M | 18.86M | 14.50M |
| Cash from Investing | 29.00M | 34.00M | 33.02M | 18.84M | 14.45M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 108.12M | -- | 65.29M | -- | -- |
| Repurchase of Common Stock | -- | -201.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 108.12M | -201.00K | 65.29M | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 92.50M | -4.73M | 69.55M | -539.00K | -12.09M |